Hemostemix Inc. (CVE:HEM – Get Free Report) shares dropped 14.5% during mid-day trading on Tuesday . The company traded as low as C$0.27 and last traded at C$0.27. Approximately 438,482 shares were traded during mid-day trading, a decline of 36% from the average daily volume of 690,023 shares. The stock had previously closed at C$0.31.
Hemostemix Stock Performance
The stock has a market capitalization of C$23.09 million, a P/E ratio of -13.25 and a beta of 0.20. The firm has a 50-day moving average price of C$0.11 and a 200 day moving average price of C$0.08.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Read More
- Five stocks we like better than Hemostemix
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- 3 Dividend Stocks Rewarding Investors With Buybacks
- 3 Stocks to Consider Buying in October
- Tech Titans in Chips: 3 Semiconductor Stocks Worth Buying Now
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Why SoundHound AI’s Setback Could Be a Buying Opportunity
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
